PharmaEssentia’s 'What Counts' campaign as featured on Besremi's official website

February 22, 2023 11:56 AM EST

PharmaEssentia takes Besremi rare blood cancer message to consumers

Beth Snyder Bulik

Senior Editor

PharmaEssentia’s first product Besremi is the only first-line treatment approved for polycythemia vera (PV). Now marketed for more than a year, the drugmaker is ready …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PharmaEssentia takes Besremi rare blood cancer message to consumers

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Phar­maEssen­tia takes Besre­mi rare blood can­cer mes­sage to con­sumers

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

PharmaEssentia takes Besremi rare blood cancer message to consumers